.jpg)
STAT+: Your money or else: Some drug makers could be ‘highly’ susceptible to ransomware attacks
The latest high-profile incident of a ransomware attack caused one of the biggest gas and…
Category: Pharma
STAT+: Pharmalittle: G20 nations water down Covid-19 IP waiver; Biden hopes to grow U.S. share of global vaccine market
Top of the morning to you, and a fine one it is. We enjoy this…
STAT+: Feds tell drug makers to offer discounts to safety-net hospitals or face penalties
After a year of controversy, the Health Resources and Services Administration notified six large drug…
STAT+: Pharmalittle: Sanofi and Glaxo tout positive Covid-19 vaccine results; Pfizer exec warns IP waiver will cause materials shortage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Congress grills U.S. trade representative over Covid-19 IP waiver; Pfizer shot was target of conspiracy theories
Once again, another working week will soon draw to a close. If you are surprised…
STAT+: Charles River loses a battle over harvesting horseshoe crabs used for testing bacteria in drugs
In a setback to Charles River Laboratories (CRL), a federal judge temporarily blocked its contractors…
.jpg)
STAT+: Pharmalittle: Top Emergent execs will testify before Congress; most Americans don’t trust the FDA or CDC
Top of the morning, and a fine one it is. Clear blue skies and crisp…
STAT+: Brazil’s Supreme Court rules that patent extension rules are unconstitutional
The Brazilian Supreme Court ruled that a provision in the country’s intellectual property law allowing…
STAT+: Most Americans believe Biden is correct to support an IP waiver for Covid-19 vaccines
Nearly two in three Americans believe the Biden administration is correct to support a waiver…
STAT+: A clinical trial coordinator is indicted for falsifying data in a Glaxo asthma drug study
A former study coordinator at a company hired to run a clinical trial of a…
STAT+: Pharmalittle: Key Dems push Pelosi to seek ‘bipartisan’ drug pricing reform; AstraZeneca CEO pay upsets shareholders
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Sanofi is accused of ‘widespread destruction’ of company e-mails tied to Zantac recalls
As litigation proceeds over the Zantac heartburn pill and a possible carcinogen, a court filing…
STAT+: Pharmalittle: U.K. says IP waiver is insufficient for Covid-19 vaccine access; EU sues AstraZeneca over vaccine supply — again
Rise and shine, another busy day is on the way. We can tell because our…
STAT+: Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price
In a challenge to Novartis (NVS), a Dutch advisory body has recommended that the government…
STAT+: Pharmalittle: Novavax sees delay in seeking emergency use of its Covid-19 shot; AstraZeneca CEO’s pay causes a stink
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: WHO, international regulatory group urge pharma to publish clinical study reports
In a significant step toward greater transparency, the World Health Organization and the International Coalition…
STAT+: Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 shot; EU is willing to explore Covid-19 IP waiver
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Massachusetts sues Publicis for designing ‘marketing schemes’ to boost OxyContin sales
The Massachusetts attorney general has filed a lawsuit against Publicis Health, one of the world’s…
STAT+: The U.S. opened pandora’s box on IP waivers for Covid-19 vaccines. What happens now?
In a surprising move, the Biden administration has said it will support a controversial proposal…
STAT+: In Belgium, too many clinical trial sponsors waffle about reporting required results
The results of more than one-fifth of clinical trials that were conducted in Belgium have…
STAT+: Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is cost-effective at $2,500
Good morning, everyone, how are you today? We are doing just fine, thank you, as…
STAT+: Incyte pays $12.6 million to resolve claims it paid drug kickbacks through charity
Incyte (INCY) agreed to pay $12.6 million to settle allegations that donations amounted to kickbacks…
STAT+: Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year
The controversial, but widely anticipated Biogen (BIIB) treatment for Alzheimer’s would only be cost-effective if…
U.S. will back proposal to waive patent rights and boost Covid-19 vaccine production
In a significant move to combat the Covid-19 pandemic, the U.S. government agreed to support…
STAT+: Pharmalittle: Pharma showers a key Democratic senator with cash; Lilly exec accused of altering factory documents
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Rising wholesale drug prices really do matter to half of all commercially insured Americans
Although the pharmaceutical industry argues that wholesale prices do not accurately reflect prescription drug costs,…
STAT+: Pharmalittle: Pfizer Covid-19 vaccine to generate $26 billion in 2021 sales; EMA reviews Sinovac Covid-19 vaccine
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Gilead sues Russia over a compulsory license issued to a company making remdesivir
Amid worldwide clamoring for Covid-19 vaccines and other therapies, Gilead Sciences (GILD) last month filed…
STAT+: European Commission fines a Merck KGaA unit for providing misleading info prior to a merger
The European Commission fined a unit of Merck KGaA $9 million for providing incorrect or…
STAT+: Pharmalittle: U.S. trade rep to talk with WTO about IP and Covid-19 vaccines; WHO’s Tedros plans to seek re-election
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Brazilian senate votes to suspend patents in bid to widen access to Covid-19 vaccines
After a year of politicking, the Brazilian senate passed a bill that would permit the…
STAT+: Pharmalittle: Wyden goes back to the drawing board on drug pricing; Emergent undergoes an executive shake-up
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Did someone say patent thicket? AbbVie CEO to testify before Congress about drug pricing tactics
As part of its probe into pharmaceutical industry pricing tactics, a Congressional committee next month…
STAT+: Global spending on medicines could hit $1.6 trillion by 2025 — and that doesn’t include Covid-19 vaccines
Global spending on medicines is forecast to grow between 3% and 6% annually and reach…
STAT+: Pharmalittle: Biden issues ’empty call’ for drug pricing reform; FDA threatens to fine company for not posting trial results
Top of the morning to you, and a fine one it is. Gray skies are…
STAT+: Americans paid two to four times as much for some drugs as in three other countries
Amid national angst over the cost of prescription drugs, a new analysis finds that U.S….
STAT+: For the first time, the FDA may fine a drug maker for failing to post clinical trial results
The Food and Drug Administration is threatening to fine Acceleron Pharma (XLRN) for failing to…
STAT+: Pharmalittle: Pfizer Covid-19 pill could be ready by year-end; Warren urges SEC to probe Emergent CEO over stock sales
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Will India issue sidestep patents on a pair of pricey — but lifesaving — TB drugs?
A widely anticipated court hearing will be held in India on Wednesday over the cost…
Biogen to expand access to its ALS drug, but move may come too late for some patients
After weeks of controversy, Biogen (BIIB) has agreed to provide an experimental drug for combating…
STAT+: Pharmalittle: What will Biden say about drug pricing? U.S. trade rep meets with drug makers over WTO proposal
Rise and shine, folks, another busy day is on the way. We can tell because,…
STAT+: Thanks to its Covid-19 response, pharma’s reputation among patient groups is climbing
Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe…
STAT+: U.K. lawmakers want Boris Johnson to disclose emails with pharma about a WTO proposal on Covid-19 vaccines
Two dozen U.K. lawmakers called on the government to publish all communications with drug makers…
STAT+: Down and out Down Under? Bristol Myers fights an ‘unreasonable’ Australian law over patents
Two big drug makers are challenging a provision in Australian patent law that they argue…
STAT+: Pharmalittle: Emergent CEO sold stock before vaccine contamination was reported; Biden urged to support WTO proposal
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Millions sign petitions urging the U.S. to back a WTO proposal for greater Covid-19 vaccine access
More than two million petitions were sent to the White House in hopes of convincing…
STAT+: The price of a Vertex cystic fibrosis treatment stirs anger in Australia
The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals (VRTX)…
STAT+: New data point to benefits of Bristol’s novel psoriasis pill, but safety issues will be scrutinized
Last November and then again in February, Bristol Myers Squibb said its oral drug designed…
STAT+: Pharmalittle: CDC committee to vote on J&J Covid-19 vaccine; has the White House written off the J&J shot?
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘There are no alternatives’: As Pfizer discontinues an old glaucoma drug, a small group of patients struggles to cope
Next month, an eye drop that Carol Vaghar has taken for the past few years…